Panitumumab (anti-EGFR) |
| Catalog No.GC66333 |
Le panitumumab (anti-EGFR) est un anticorps monoclonal IgG2 anti-EGFR entièrement humain avec une activité anti-tumorale. Le panitumumab (anti-EGFR) inhibe la prolifération, la survie et l'angiogenèse des cellules tumorales. Le panitumumab (anti-EGFR) peut être utilisé dans la recherche de cancers, comme le cancer du cÔlon.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Panitumumab (anti-EGFR) is a fully human IgG2 anti-EGFR monoclonal antibody with anti-tumor activity. Panitumumab (anti-EGFR) inhibits tumor cell proliferation, survival and angiogenesis. Panitumumab (anti-EGFR) can be used in the research of cancers, such as colon cancer[1][2][4].
Panitumumab (2 nM-2 μM, 3 h) (anti-EGFR) inhibits ligand-dependent autophosphorylation in EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells[3].
Panitumumab (0-200 μg/mL, 48 h) (anti-EGFR) inhibits the proliferation of DLD-1 cells[4].
Panitumumab (80 μg/mL, 24 h) (anti-EGFR) increase beclin-1 (a marker of autophagy) levels in Caco-2 cells and DLD-1 cells[4].
Western Blot Analysis[3]
| Cell Line: | EGFR-expressing NCI-H1975 cells, NCI-H1650 cells and CHO cells |
| Concentration: | 2, 20, 200, 2000 nM |
| Incubation Time: | 3 h |
| Result: | Inhibited ligand-induced autophosphorylation of EGFR. |
Panitumumab (25, 100, or 500 μg/mouse, i.p., twice a week) (anti-EGFR) inhibits tumor growth in NCI-H1975 and NCI-H1650 xenografts, compared with control (P < 0.0003)[1].
| Animal Model: | NCI-H1975 and NCI-H1650 xenografts[3] |
| Dosage: | 25, 100, or 500 μg/mouse |
| Administration: | Intraperitoneal injection (i.p.), twice a week |
| Result: | Inhibited ligand-induced EGFR phosphorylation, tumor growth, and markers of proliferation. Decreased Ki-67 and phospho- mitogen-activated protein kinase (pMAPK) staining in both xenografts. |
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *